Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company specializing in endocrine diseases and tumors, has announced its participation in two upcoming investor conferences in New York this September. The company will engage in fireside chats at:
1. The Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, at 5:35 p.m. ET
2. The Cantor Global Healthcare Conference on September 18, 2024, at 8:35 a.m. ET
Both events will be webcast live and archived on Crinetics' website. Investors interested in 1x1 meetings with management should contact their conference representatives.
Positive
- None.
Negative
- None.
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference both being held in New York, NY in September.
Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside chat on Wednesday, September 4, 2024 at 5:35 p.m. Eastern Time
Webcast link HERE
Cantor Global Healthcare Conference
Fireside chat on Wednesday, September 18, 2024 at 8:35 a.m. Eastern Time
Webcast link HERE
The live and archived webcasts will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events.
If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.
ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is an investigational, first-in-class, oral, once-daily somatostatin receptor type 2 (SST2) agonist in Phase 3 clinical development for acromegaly and in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
When is Crinetics Pharmaceuticals (CRNX) participating in the Morgan Stanley Healthcare Conference?
What is the date and time for Crinetics Pharmaceuticals' (CRNX) fireside chat at the Cantor Global Healthcare Conference?
Where can investors access the webcasts of Crinetics Pharmaceuticals' (CRNX) conference presentations?
How can investors arrange 1x1 meetings with Crinetics Pharmaceuticals' (CRNX) management at these conferences?
